US FDA’s Tough Road Ahead In Creating Pathway For Life-Saving Biologics
The US Food and Drug Administration heard from myriad pharmaceutical companies, patient groups, and other stakeholders last week as the agency considers how to create an abbreviated pathway to bring more biologic drugs to market.

Daniele Dionisio writes: The current break-through of multinational drug corporations in India couples with the protectionist policies pursued by the US and EU and with India’s obligations as a WTO member. Taken together, these realities mean a heavy threat to India’s freedom as independent provider of lifesaving, affordable and state-of-the-art antiretroviral medicines to the resource-limited countries.